AbCellera Biologics (ABCL) Revenue (2020 - 2023)
AbCellera Biologics' Revenue history spans 4 years, with the latest figure at $9.2 million for Q4 2023.
- For the quarter ending Q4 2023, Revenue fell 57.4% year-over-year to $9.2 million, compared with a TTM value of $9.2 million through Sep 2024, down 81.78%, and an annual FY2024 reading of $28.8 million, down 24.17% over the prior year.
- Revenue for Q4 2023 was $9.2 million at AbCellera Biologics, up from $6.6 million in the prior quarter.
- The five-year high for Revenue was $316.6 million in Q1 2022, with the low at $4.7 million in Q1 2020.
- Average Revenue over 4 years is $70.7 million, with a median of $16.9 million recorded in 2022.
- Year-over-year, Revenue surged 4253.47% in 2021 and then plummeted 96.15% in 2023.
- Tracing ABCL's Revenue over 4 years: stood at $207.9 million in 2020, then crashed by 32.98% to $139.3 million in 2021, then tumbled by 84.54% to $21.5 million in 2022, then plummeted by 57.4% to $9.2 million in 2023.
- Per Business Quant, the three most recent readings for ABCL's Revenue are $9.2 million (Q4 2023), $6.6 million (Q3 2023), and $10.1 million (Q2 2023).